Buy / Sell / Rent for investment and live in residences in NYC

Medical imaging AI

Prevent development of coronary disease by identifying risk via consumer genomics and connecting to consumer health services like OPTAVIADetect and Diagnose coronary disease using consumer pay Heart Calcium ScanTreat disease with connected consumer focused digital health IoT devices

Lead in Fibrosis Imaging, including MRI, MRE, PET tracerLead Prostate OncologyDigital Health StrategyCRO Optimization

CETA consists of (1) Cerner consulting; (2) ETL tools, including intelligent neural network based data extraction, document labeling, database creation from digital documents containing unstructured data; (3) healthcare data analytics; (4) quality and process impprovement consulting based on data analytics.1. Developing CETA partners for innovation in healthcare information technology (HIT).2. Assist startups to take technologies to the market. 3. Commercialize clinical alogirthms.4. Establish clinician networks relevant to HIT technology.5. Raise investor funding for CETA, primary through clinician investors

Clinical Pathways committee at New York Presbyterian Hospital, chaired by Karen Scott MD MPH,Vice President of Quality & Patient Safety.o Helped develop metrics for pathways and mockup dashboards for leadership, attendingphysician, and trainee physician users.

• Clinical Resource Optimization (CRO) committee in the New York Presbyterian Hercules Initiative: improving quality via minimizing unnecessary advanced imaging and interventional procedures.• Clinical Pathways committee at New York Presbyterian Hospital. • Faculty Advisor for the Housestaff Quality Council, New York Presbyterian• High clinical productivity accounting for 75% of Abdominal Division profits for 2012-13.

Improving quality via increasing efficiency, chaired by Jaclyn Mucaria, MPA, Senior Vice President ofAmbulatory Care & Patient Centered Care Services .o Future Outpatient Orders: a method to order outpatient Radiology exams during the inpatienthospitalization to facilitate discharge planning and reduce non-urgent inpatient testing- Presented to the committee, formed the team to represent the needed skills andstakeholders (hospital administration, Radiology, clinical services that use Radiology,IT, Allscripts / Eclipsys EMR IT, nursing). This multidisciplinary approach taught methe most efficient and comprehensive manner in which to implement positive change.o Inpatient FDG PET CT: Required Nuclear Medicine attending approval to perform oninpatients.- Created Eclipsys ordering mechanism that informed clinicians of the approvalrequirement- Reduced inpatient exams by 60%o Duplicate inpatient radiology orders- Eclipsys based check for an existing duplicate radiology order to avoid duplicateimaging

Reviewing imaging, including CT, MRI, and nuclear medicine, for oncology trials focused on a variety of cancers, including prostate and liver. Perform volumetric and RECIST based measurements of tumor as biomarkers in oncology trials.

• Updated Liver MRI and Liver Donor imaging protocols; standardized reporting• Run weekly multidepartment Liver Conference• Updated Prostate MRI protocols; standardized reporting• Implemented standardized Powerscribe reporting templates for abdominal and pelvic CT and MRI • Perform volumetric and RECIST based measurements of tumor as biomarkers in oncology trials at Columbia and as part of Clinical Research Organizations (CRO)Clinical Trials examples- A Randomized, Double-Blind, Placebo- Controlled Phase II Study of VTX-2337 (IND#78,416) in Combination with Pegylated Liposomal Doxorubicin in Patients with Recurrent orPersistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.- A Phase 3 Randomized, Double- Blind, Placebo- Controlled, Multi- Center Study of Amg 386With Paclitaxel and Carboplatin as First line treatment of SUbjects With FIGO Stage III-ivEpithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers.- Feasibility of Carboplatin, Paclitaxel and Bevacizumab Neoadjuvant Therapy for EpithelialOvarian, Fallopian Tube and Primary Peritoneal Cancer- Phase II study: Neoadjuvant Gemcitabine, Docetaxel and Capecitabine Followed byNeoadjuvant Radiation Therapy with Gemcitabine and Capecitabine in the Treatment of StageII to III Pancreatic Adenocarcinoma.- A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacyand Safety of GS-6624 Combined with Gemcitabine as First Line Treatment for MetastaticPancreatic Adenocarcinoma.- A Phase III Multicenter, International, Randomized, Double-blind, Placebo- controlled Study ofDoxorubicin Plus Palifosfamide-tris vs. Doxorubicin Plus Placebo in Patients with Front-lineMetastatic Soft Tissue Sarcoma

Assistant Professor, Body Imaging, Yale University School of Medicine, 2010-2011Instructor, Body Imaging, Yale University School of Medicine, 2009-2010• Established collaboration with Gastroenterology that increaesd MR Enterographies from 0 per week to 2-4 cases per week after a 12 month period.• Perform volumetric and RECIST based measurements of tumor as biomarkers in oncology trials.

Clinical and Translational Fellowship in Body MRI